MRNA's earnings and revenues surpass estimates in the fourth quarter of 2024. The company reiterates 2025 total revenue ...
Sojo now focuses on the development of business-to-business propositions and is adopting an in-house operations model.
Vertex Pharmaceuticals (VRTX) stock gets an upgrade from Canaccord Genuity after its Q4 2024 results on Tuesday, Read more here.
Hosted on MSN3d
Cabinet member's kid took life-changing drug — but he's now 'shutting that door': reportThe daughter of a key architect of Project 2025 benefitted from a life-changing drug — which was created with the help of the ...
Vertex reports mixed fourth-quarter 2024 results as earnings miss estimates while revenues beat the same. Trikafta/Kaftrio ...
Barclays raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $467 from $435 and keeps an Equal Weight rating on the shares. The ...
Barclays analyst Gena Wang maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target of $467.00.
When you’re craving something sweet, donuts are the perfect treat. However, you may want to stick to Dunkin' or Krispy Kreme.
The cystic fibrosis treatment leader exceeded revenue expectations, but missed slightly on earnings per share.
Impress your Valentine at 980 Prime Steakhouse at the Chamonix Casino Hotel in Cripple Creek. Enjoy great food, wine pairings, and a romantic setting.
Axcelis Technologies, Inc. today announced financial results for the fourth quarter and full year ended December 31, 2024. For ...
Vertex (VRTX) stock was trading largely flat post-market after the company released its Q4 earnings report and issued 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback